Anthem Denied Ozempic or GLP-1? Here's How to Appeal

Anthem, which operates as Elevance Health and runs Blue Cross Blue Shield plans in 14 states, has become one of the most prominent — and most contested — insurers when it comes to GLP-1 receptor agonist medications like Ozempic (semaglutide), Wegovy, Mounjaro (tirzepatide), and Zepbound. Whether Anthem denied your prescription because of step therapy requirements, formulary placement, or a distinction between diabetes and obesity indications, you have real options to challenge that decision.

Why Insurers Deny Ozempic and GLP-1 Claims

Anthem's approach to GLP-1 medications is bifurcated based on indication, and this creates significant confusion for members and providers alike.

For Type 2 diabetes (ICD-10: E11.9): Ozempic (semaglutide) and similar GLP-1 medications are generally covered when prescribed for diabetes management — but Anthem's formulary places them in higher tiers (Tier 3 or Tier 4 specialty) and almost always requires Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization. Anthem's prior authorization criteria typically require: documented Type 2 diabetes diagnosis, an A1C at or above a threshold (often 7.5% or higher), and evidence that first-line medications like metformin have been trialed. Starting directly on a GLP-1 without metformin typically results in a step therapy denial.

For obesity/weight management (ICD-10: E66.9, E66.01): Wegovy (semaglutide for weight loss) and Zepbound (tirzepatide for weight loss) are FDA-approved for chronic weight management, but many Anthem employer-sponsored plans explicitly exclude weight loss medications as a covered benefit. When obesity medication coverage exists, Anthem's clinical criteria typically require: BMI of 30 or higher (or 27+ with a qualifying comorbidity like hypertension, type 2 diabetes, or sleep apnea G47.33), documented failure of a physician-supervised diet and exercise program, and sometimes a behavioral health evaluation.

The formulary paradox: A member prescribed Ozempic primarily for diabetes control who also loses weight may have the prescription approved — while a member prescribed Wegovy specifically for obesity on the same plan has it denied, even though the active ingredient (semaglutide) is identical. This distinction is plan-specific and can be challenged when clinical evidence shows the medication is necessary regardless of the primary indication.

How to Appeal

Step 1: Identify the Specific Denial Reason

Step therapy non-compliance, plan exclusion, formulary criteria, and prior authorization failure each require a different appeal argument. Read the denial letter carefully and request Anthem's Clinical Policy Bulletin for the denied medication at anthem.com/provider/policies.

Step 2: File a First-Level Internal Appeal Within 180 Days

For step therapy denials: provide documentation that earlier-step medications were trialed and failed, were contraindicated, or that the requested medication is clinically superior. For medical necessity denials: submit a letter of medical necessity from your prescribing physician documenting diagnosis, BMI, A1C, comorbidities, and clinical rationale. For plan exclusions: investigate whether your plan actually excludes obesity medications versus having a formulary restriction — these are treated differently under ERISA.

Step 3: Assert Step Therapy Exception Rights Where Applicable

Many states have enacted step therapy exception laws requiring insurers to grant exceptions when a patient has already tried the required medications, when those medications are contraindicated, or when the requested medication is clinically superior. States with step therapy exception laws applicable to Anthem's fully insured plans include Indiana, Virginia, Colorado, Connecticut, New York, and others. Cite the specific statute in your appeal — for example, Virginia Code § 38.2-3407.15 or Indiana Code § 27-8-17-3.

Step 4: Document Cardiovascular Indication if Applicable

For patients with established cardiovascular disease, GLP-1 medications have FDA-approved cardiovascular risk reduction indications — the SELECT trial demonstrated a 20% reduction in major cardiovascular events with semaglutide in non-diabetic patients with cardiovascular disease. Cardiovascular risk reduction is a separate approved indication that may require a different prior authorization pathway than diabetes or obesity and may not be subject to the same step therapy requirements.

Step 5: Request a Clinical Reviewer With Endocrinology or Obesity Medicine Specialty

File a second-level internal appeal if the first is denied, requesting a clinical reviewer with endocrinology or obesity medicine specialty. Under ERISA (29 U.S.C. § 1133), you have the right to know the reviewer's qualifications — a formulary denial reviewed by someone without the relevant specialty expertise is procedural grounds for escalation.

iro-review">Step 6: Request External IRO Review

For step therapy denials violating state exception laws, IRO reversal rates are high. File for External Independent Review: Complete Guide" class="auto-link">external review under 45 CFR 147.136 and contact your state's Department of Insurance if Anthem violated applicable step therapy exception statutes.

What to Include in Your Appeal

• Prescribing physician's letter of medical necessity: diagnosis with ICD-10 codes, BMI, A1C if diabetic, comorbidities, and specific clinical rationale for this medication over alternatives
• Documentation of prior medications trialed: names, doses, duration of trial, and reason for discontinuation or failure — this is the most critical document for step therapy appeals
• For obesity indication: documentation of physician-supervised diet and exercise program participation and outcomes, demonstrating that lifestyle intervention alone is insufficient
• Applicable state step therapy exception statute with relevant provisions highlighted, and citation of the specific step therapy exception criteria met
• For cardiovascular risk patients: documentation of CV risk factors and reference to SELECT trial evidence supporting GLP-1 cardiovascular benefits as a distinct indication

Fight Back With ClaimBack

Anthem's GLP-1 denials are exploding as these medications become more widely prescribed — and so are successful appeals. Whether your denial is about step therapy, a plan exclusion, or a prior authorization criterion, the key is understanding exactly which rule Anthem applied and building an appeal that directly dismantles it. ClaimBack generates a professional appeal letter in 3 minutes that addresses your specific denial type and cites the clinical trial evidence and state law protections that matter most for GLP-1 appeals. Start your free claim analysis → Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal